Insmed (NASDAQ:INSM) Stock Sees Heavy Call Option Buying

Insmed, Inc. (NASDAQ:INSM – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors acquired 7,564 call options on the company. This represents an increase of approximately 85% compared to the average daily volume of 4,092 call options.

Insider Buying and Selling

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 101,100 shares of the stock in a transaction that occurred on Thursday, November 19th. The shares were sold at an average price of $145.26, for a total transaction of $14,685,786.00. Following the sale, the insider directly owned 41,895 shares in the company, valued at $6,085,667.70. This represents a 70.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. This represents a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ethic Inc. grew its position in Insmed by 109.9% during the third quarter. Ethic Inc. now owns 10,498 shares of the biopharmaceutical company’s stock valued at $1,198,000 after acquiring an additional 5,496 shares during the period. Banco Santander S.A. purchased a new position in shares of Insmed in the 3rd quarter worth about $1,043,000. C WorldWide Group Holding A S raised its holdings in shares of Insmed by 62.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock worth $27,840,000 after purchasing an additional 100,000 shares during the period. Motley Fool Asset Management LLC purchased a new position in shares of Insmed in the 3rd quarter worth about $2,034,000. Finally, Empowered Funds LLC lifted its stake in shares of Insmed by 32.6% in the 1st quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after purchasing an additional 12,775 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on INSM shares. Stifel Nicolaus set a $195.00 target price on Insmed in a report on Thursday, October 29th. Benchmark restated a “buy” rating on shares of Insmed in a report on Monday, November 2nd. Evercore reaffirmed an “outperform” rating and issued a $170.00 price target on shares of Insmed in a research report on Friday, August 7th. The Goldman Sachs Group began coverage on Insmed in a research note on Thursday, September 24th. They issued a “buy” rating and a $188.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $196.52.

View Our Latest Research Report on INSM

Insmed Price Performance

Shares of INSM opened at $141.33 on Friday. The firm’s fifty day simple moving average is $111.09 and its 200-day simple moving average is $122.71. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.

Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.75) EPS. As a group, equities research analysts expect that Insmed will post -1.86 EPS for the current year.

More Insmed News

These are some of the INSM news items that stood out recently:

  • Positive Sentiment: Reports that Sanofi is exploring a potential acquisition drove a strong rally in Insmed shares. One analyst cited in coverage suggested a takeover could value the stock at $170–$210 per share, although no deal has been announced. Insmed shares jump as Sanofi weighs potential takeover
  • Neutral Sentiment: An Insmed insider sold 101,100 shares, reducing her stake by about 71%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may temper concerns that the sale reflects a reaction to recent developments.
  • Negative Sentiment: The takeover reports are speculative, and analysts are divided over whether a deal would bring pipeline benefits or create financial strain. The lack of a confirmed offer may contribute to caution and profit-taking after the previous session’s surge. Analysts split on potential Sanofi-Insmed deal

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

See Also

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.